Canada-based biotechnology company AbCellera (Nasdaq: ABCL) has signed a multi-year collaboration and license agreement with Everest Medicines Limited (HKEX 1952.HK), a biopharmaceutical company, to discover therapeutic antibodies for up to 10 targets chosen by Everest Medicines, it was reported on Wednesday.
The collaboration is intended to provide support in expanding Everest's range of novel medicines across multiple indications, with the initial programs concentrating on targets in oncology.
By partnering with AbCellera, Everest will benefit from an operating system that supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access. The collaboration will leverage the full breadth of AbCellera's technology stack, including sourcing fully humanised antibodies from the Trianni Mouse, sourcing single domain antibodies from camelids, and combining any two antibodies to create native bispecifics using the OrthoMabTM protein engineering platform.
According to the terms of the contract, Everest will have the rights to develop and commercialise antibodies resulting from the partnership. AbCellera is to receive research payments and is eligible to receive from Everest downstream clinical and commercial milestone payments and royalties on net sales of products.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients